This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Haskins K. Kashima, MD, Associate Professor, Department of Otolaryngology—Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, representing the 12-institution Papilloma Study Group, reported that interferon α-N1 was found effective as an adjuvant to endoscopic excision in respiratory papillomatosis. The findings of the prospectively randomized six-month study were gathered from 56 patients, 28 of whom received interferon and 28 of whom received no interferon. The anatomic extent of disease was objectively scored in all patients at endoscopic operations performed at two-month intervals; the median scores showed a statistically significant improvement in patients receiving interferon. Improvement in disease severity occurred irrespective of age, sex, duration of disease, HPV-6 subtype, or the presence or absence of a tracheotomy. Toxicity was "tolerable" and the agent was considered safe.
The investigators stated that a longer period of interferon administration may be needed for maximum improvement; some of the study patients are presently
BAILEY BJ. Interferon α-N1 in Respiratory Papillomatosis. Arch Otolaryngol. 1986;112(1):19. doi:10.1001/archotol.1986.03780010021004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: